The PI3K-β inhibitor AZD8186 was investigated in PTEN-deficient breast and prostate cancer because PTEN-deficient cancers often rely on the PI3Kβ pathway for survival, making it a viable therapeutic target [62]. Here, PTEN is linked to prostate carcinoma.